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Summary A series of tumour related markers have been examined in 179 patients receiving primary
endocrine therapy for metastatic breast cancer. Significant correlations between therapeutic response (UICC
criteria after 6 months of treatment) and appropriate alterations in serum concentrations of carcinoembryonic
antigen, ferritin, c-reactive protein, orosomucoid and the erythrocyte sedimentation rate, have been observed
when changes in these markers were examined only at high serum concentrations. By combining these five
markers a 'therapeutic index' of response has been devised which can be employed at an early stage of
treatment in more than 90% of patients, giving an overall sensitivity/specificity of 90%/78% for therapeutic
response or disease stabilisation over a 6-month period. The design of an objective measurement of response,
which is easy to perform, has the potential to replace the existing, largely subjective, UICC criteria for
retrospective judgement of response, and may also be used to direct systemic endocrine therapy.
Many systemic treatments are now available for the pallia-
tion of disseminated breast cancer. In the absence of an
immediate threat to life, endocrine therapy remains the initial
treatment of choice, due to its relative lack of toxicity. An
early and accurate assessment of response to endocrine
therapy would be of value, in order to allow a timely altera-
tion of treatment in unresponsive patients. At present, such a
decision is based upon ill defined clinical criteria, although
the International Union Against Cancer (UICC) have sug-
gested guidelines for the retrospective judgement of response
in clinical trials (Hayward et al., 1977).
Previous reports have explored the role of tumour markers
in an attempt to measure therapeutic response objectively
throughout treatment (Chu & Nemoto, 1973; Steward et al.,
1974; Borthwick et al., 1977; Tormey et al., 1977a, b;
Haagenson et al., 1978; Lamerz et al., 1980; Haagenson et
al., 1980; Lee, 1983; Krieger et al., 1983; Coombes et al.,
1983; Campbell et al., 1983; Heim et al., 1984; Hortobagyi et
al., 1984). Few studies have examined the potential of a
combination of markers recorded simultaneously, despite
indications that this approach might prove rewarding
(Coombes et al., 1977; Woo et al., 1978; Cowen et al., 1978;
Cove et al., 1979; Caffier & Brandau, 1983).
This study describes an assessment of response to endo-
crine therapy which employs a combination of five tumour
markers, and compares this biochemically based assessment
with that achieved using the accepted clinical criteria after 6
months of treatment. The majority of tumour markers for
advanced breast cancer have lacked specificity for the deter-
mination of response, as they have been employed at low
concentrations which are frequently found in tumour-free
women. The present study attempts to correct this by utilis-
ing markers only when concentrations exceed predefined high
levels (above the ninetieth centile for control populations).
Patients and methods
One hundred and seventy-nine patients who presented to our
clinic over a 2-year period were studied. All had advanced
recurrent breast cancer and all received endocrine therapy as
initial treatment for overt metastases. Treatment was pre-
scribed according to several protocols and consisted of
tamoxifen (Nolvadex, 20 mg b.d.) or megestrol acetate
(Megace, 160 mg b.d.) in post-menopausal patients, and
oophorectomy or a luteinising hormone-releasing hormone
agonist (Zoladex, ICI 118630) in premenopausal patient.
Menopausal status was confirmed using luteinising hormone
and follicle stimulating hormone levels in women who had
previously undergone hysterectomy, or who presented within
5 years after natural cessation of menstruation.
The oestrogen receptor status (ER) of primary tumour
tissue had been documented in 109 patients; 51% were ER
positive (greater than 5 fmol mg-' cytosol protein). ER
estimations were performed at the Tenovus Institute, Cardiff,
using the dextran coated charcoal method (Nicholson et al.,
1981).
All patients were staged before treatment in an advanced
breast cancer clinic. All but six patients had received no
previous endocrine treatment for overt metastases. Addi-
tional symptomatic treatments were prescribed throughout
the study which included systemic analgesics, steroids and/or
bronchodilators for lung metastases, and radiotherapy for
skin ulceration or localised bone pain. Patients unassessable
to hormonal therapy by either the type of presenting disease
or the addition of local treatments were not included in the
study. Sixteen patients were excluded from analysis as
sequential serum samples were not available because of early
death. The patients studied, therefore, represented the great
majority of those attending one unit over a 2-year period,
who received endocrine therapy for assessable metastatic
disease.
Initial staging included a full clinical examination,
documentation of the Karnofsky performance status (Kar-
nofsky & Burchenal, 1948) and accurate measurement of
local and regional disease, with photography when con-
sidered helpful for later evaluation of response. Radiological
assessment consisted of lateral and antero-posterior views of
the skull, chest, dorso-lumbar spine, pelvis and upper femora
(limited skeletal survey). Painful sites of disease at other
locations were X-rayed when clinically indicated. Isotope
bone, liver and brain scans were requested only if clinically
indicated.
Haematological assessment consisted of measurement of a
full blood count, urea and electrolytes, serum calcium and
albumin, the erythrocyte sedimentation rate and liver func-
tion tests (gamma-glutamyl transaminase, alanine transferase,
alkaline phosphatase and bilirubin). In addition, several
other 'tumour related markers' were assessed sequentially
throughout active treatment (Table I). These included two
oncofetal proteins, serum carcinoembryonic antigen (CEA)
and ferritin; two acute phase proteins, c-reactive protein
(CRP) and orosomucoid; and the hormone beta human
chorionic gonadotrophin (B-HCG). Calcium excretion (CAE)
and the hydroxyproline creatinine ratio (OHP/CR) were
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Table I Tumour markers studied
Upper limit ofnormal
adoptedfor study
Serum (allpatients)
Carcinoembryonic antigena 6 ngml-'
Ferritina 220 Ag 1-'
C-Reactive proteina 10 mg 1-'
Orosomucoida 1.2 g 1-'
Erythrocyte sedimentationa 20 mm h-
Gamma-glutamyl transpeptidase 50 U I-'
Alanine aminotransferase 50 U I-'
Alkaline phosphatase 300 U 1'
Beta human chorionic gonadotrophin
Urine (bone metastases only)
Hydroxyprolene/creatinine ratio
Calcium excretion
aTumour markers combined to form therapeutic index for response.
recorded throughout treatment in the urine of a subgroup of
patients presenting with bone metastases (n = 152 for CAE,
n = 94 for OHP/CR).
Controls
Marker levels were established in women with benign breast
disease attending a diagnostic breast clinic (controls, n = 55
for analysis of CEA and ferritin; n = 25 for analysis of acute
phase proteins). These women had a mean age of 49 years
(range 28-85) and presented with histologically confirmed
benign breast lumps, breast pain or cysts.
The pre-treatment concentration of each marker in stage
IV disease was also compared with that found in 87 patients
witli untreated stage III breast cancer (see Results).
Follow-up
Patients were reviewed at 1-3 monthly intervals. Those with
bone metastases provided a fasting, early morning urine sam-
ple for the measurement of CAE and the OHP/CR ratio. The
Karnofsky performance status was recorded at each visit,
venous blood was withdrawn for measurement of routine
haematological parameters and additional serum was cen-
trifuged, aliquoted and stored at -170°C for later evaluation
of the remaining markers.
Limited skeletal radiology was repeated after 3-4 months
and after 6 months of treatment. At the first clinical sign of
objective progression patients were prescribed alternative
treatments and therefore removed from study. All assess-
ments of clinical progress were performed without referral to
biochemical data, and both the initial documentation of
disease status and subsequent assessments of clinical progress
were performed by the same observer at each visit (M.R.W.).
Assessment ofclinical response
UICC criteria have been strictly applied with the British
Breast Group stipulation that any remission should be of at
least 6 months' duration to classify as response (British
Breast Group, 1974; Hayward et al., 1977). These criteria
require a 50% reduction in measurable tumour or objective
signs of response in evaluable, but non-measurable, sites of
disease (e.g. lung or bone metastases).
Clinical response has been categorised as 'disease progres-
sion' (greater than 25% increase in the bidimensional pro-
duct of measureable tumour or the development of new
lesions), 'objective response' (greater than 50% reduction in
the size of measurable tumour with no new lesions) or
'disease stabilisation' (no new lesions and any alteration in
tumour size lying between these two extremes). In this study
response of less than 6 months' duration has been classified
as disease progression. External review of response was per-
formed by Dr A. Howell, Christie Hospital, Manchester.
Assay techniques
Routine biochemical and haematological parameters were
measured using standard techniques.
CEA was measured using a monoclonal radiometric assay
(Tandem-R CEA, kindly provided by Hybritech UK Ltd).
The intra- and inter-assay coefficients of variation were
4.6-7.6% and 6.9-7.2%, respectively.
Serum concentrations of ferritin were measured using a
solid phase, two site radioimmunoassay. Standards were
prepared in ferritin free serum and calibrated against a WHO
ferritin reference preparation. Standards covered the range of
0- 1000fig 1-'. The estimated intra- and inter-assay
coefficients of variation, over the working range, were
3.7-5.9% and 4.6-6.0%, respectively.
Concentrations of the beta subunit of human chorionic
gonadotrophin were measured by radioimmunoassay using
an antiserum raised in rabbit against B-HCG. Standards
were calibrated against the First International Reference
Preparation (kindly provided by the National Institute of
Biological Standards and Control, London) and were
prepared to cover the range 0-640 IU1'. The intra- and
inter-assay coefficients of variation were 4.7-6.1% and
5.4-8.8%, respectively.
Serum concentrations of CRP were measured using a tur-
bidometric technique on a centrifugal fast analyser (Cen-
trifichem Roche). Changes in optical density were monitored,
using an on-line computer which calculated CRP concentra-
tions (O'Callaghan et al., 1984).
Orosomucoid was measured by immuno-turbimetry using
a centrifugal fast analyser (Centrifichem 400). Standards were
prepared from a commercially available serum (Behring Stan-
dard Human Serum, ORDT 06/07). Between batch precision
for the assay was 7% at a concentration of 0.65 g1-'.
Urinary OHP was estimated in duplicate using Hypronos-
ticon Kits (Organon).
Analysis ofresults
Pre-treatment concentrations of each tumour marker were
compared in individual patients with values recorded after
1-2, 3-4 and 5-7 months of treatment.
For each marker the correlation between alterations in
concentration and clinical assessments of response was
examined only in patients who presented with, or developed
concentrations exceeding predefined levels; the proportion of
patients that this represented for each marker is shown in the
results. The object of this was to examine markers in each
individual only when concentrations were well above those
found in the majority of women without advanced disease;
concentrations above this level may then be assumed to be
due to the tumour. Such concentrations were seen in only
2-8% of women in the control groups. The 'cut-off' chosen
for analysis also depended upon the shape of the distribution
plots for each marker.
Patients maintaining concentrations within the 'normal'
range have been considered unassessable for the marker in
question. Above this level concentrations were classified as
increasing or decreasing when they altered by more than
10% during treatment.
For statistical analysis patients with rising marker concen-
trations were combined with those in whom concentrations
remained stable. Patients with no change in clinical disease
status over 6 months, were combined with those showing
objective response. Statistical significance was assessed using
the x2 test with Yates' correction.
Finally, results of five markers were combined to form a
'therapeutic index', in order to improve the discrimination of
response after 3-4 months of treatment.
Results
Patient details and therapeutic response
One hundred and six patients presented with bone or lung
metastases alone (n = 69 and n = 37, respectively). Thirty-128 M.R. WILLIAMS et al.
eight presented with both bone and lung metastases, and 35
presented with other sites of visceral involvement (mainly
hepatic). Twenty-three per cent of patients (41/179) were
found to be premenopausal at the presentation of advanced
disease.
The overall response rate was 26% (n = 47) using UICC
criteria after 6 months. In 17% (n = 31) disease remained
static for 6 months and in 56% (n = 101) disease progressed.
Disease either responded or remained static in 64% (36/56)
of ER positive patients and in 26% (14/53) of ER negative
patients.
Correlation between therapeutic response and alterations in
individual marker concentrations
In only five markers did appropriate alterations in concentra-
tion correlate with UICC response to a degree that could be
usefully employed in clinical practice (Table II). For the
remaining markers the correlation was weak and these latter
results are not discussed further in this report.
In total, 579 serum samples were obtained for the analysis
of tumour markers in patients with stage IV disease. These
included 179 samples obtained immediately before treatment,
132 obtained after I or 2 months (from 128 patients), 131
after 3 or 4 months (from 128 patients) and 137 obtained
after 5-7 months of treatment (from 114 patients).
Only the first recorded assay result has been considered for
analysis when these were duplicated in individual patients
during a single interval of treatment. Individual results for
the five markers, recorded simultaneously on the same serum
sample, were unavailable on several occasions; four pre-
treatment results and 10 follow-up results were not available
for ESR, three follow-up results for CRP, and one for both
orosomucoid and ferritin.
For each marker, the pre-treatment concentration in stage
IV disease was compared with that found both in disease-free
women attending a diagnostic breast clinic and in a series of
patients presenting with stage III disease, in order to estab-
lish upper limits of normal.
Carcinoembryonic antigen Only one control patient present-
ed with a CEA concentration in excess of 6 ng ml-', com-
pared with 18% (16/87) of those with stage III disease and
49% (88/179) of those presenting with stage IV disease
(Figure 1, median concentrations illustrated). Alterations in
CEA during treatment have been examined only when con-
centrations exceeded 6 ng ml-'.
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Figure I Carcinoembryonic antigen in controls and at presenta-
tion of stage III and IV disease: median concentrations illus-
trated.
One hundred and twenty-eight stage IV patients had CEA
concentrations measured before and after 1 or 2 months of
treatment. Sixty-three (49% of the total) were assessable
employing a CEA concentration in excess of 6 ng ml-'. One
hundred and twenty-eight patients had CEA measurements
repeated after 3 or 4 months of treatment, 71 (55%) were
biochemically assessable as above. After 5-7 months of
treatment, 65 of 114 patients (57%) wre biochemically assess-
able. A highly significant association was found between the
clinical assessment of response after 6 months, and changes
in tumour marker concentration (above 6 ng ml-') during all
three periods of treatment (Table II: pre-treatment vs 1-2
months, x2 = 15, 1 d.f.; vs 3-4 months, x2 = 33.8, 1 d.f.; vs
5-7 months, X2 = 28.16, 1 d.f.).
Ferritin Only three control patients presented with serum
concentrations in excess of 220 jg 1I', compared with 7%
(6/87) of stage III patients and 30% (53/179) of those with
stage IV disease (Figure 2). Alterations in serum ferritin in
Table 11 Alterations in individual serum marker concentrations during treatment versus therapeutic response
Marker concentrations Marker concentrations Marker concentrations
pre-treatment versus pre-treatment versus pre-treatment versus
1-2 months treatment 3-4 months treatment 5-7 months treatment
Tumour UICC response
marker at 6 months Decrease Stable Increase Decrease Stable Increase Decrease Stable Increase
CEA Response 15 2 3 22 1 1 22 0 3
Static 5 1 3 8 1 2 11 2 2
Progression 6 9 19 5 2 29 3 1 21
(X2 = 15.1; l.d.f.)* (X2 = 33.8; I.d.f.)* (X2 = 28.16; l.d.f.)* Ferr. Response 11 4 1 13 2 0 18 1 2
Static 5 0 1 5 1 1 8 0 0
Progression 5 4 19 6 0 21 1 3 15
(X2 = 15.1; l.d.f.)* (x2 = 23.4; l.d.f.)* (X2 = 23.0; l.d.f.)* CRP Response 21 0 1 22 0 0 24 0 1
Static 9 0 2 13 0 3 14 1 3
Progression 10 3 24 9 2 24 6 0 18
(X2 = 26.52; I.d.f.)* (X2 = 30.82; l.d.f.)* (x2 = 24.7; l.d.f.)* Oroso. Response 26 2 2 25 1 2 29 3 1
Static 11 1 0 13 1 3 15 1 2
Progression 16 13 17 22 5 26 11 7 15
(X2 = 23.87; l.d.f.)* (x2 = 26.4; l.d.f.)* (x2 = 22.6; U.d.f.)* ESR Response 23 2 5 27 0 6 31 1 4
Static 11 3 1 15 0 1 15 2 3
Progression 17 6 23 11 5 32 14 0 21
(X2 = 12.24; I.d.f.)* (x2 = 36.09; I.d.f.)* (x2 = 15.21; l.d.f.)*
Statistical significance assessed by combining 'response' with 'static', and 'stable' with 'increase' *P<0.001.
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Figure 2 Ferritin in controls and at presentation of stage III and
IV disease: median concentrations illustrated.
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Figure 3 C-reactive protein in controls and at presentation of
stage III and IV disease: median concentrations illustrated.
stage IV disease have been examined only above 2201g 1-'.
One hundred and twenty-eight patients had ferritin levels
recorded before and after 1 or 2 months of treatment. Fifty
(39% of the total) were assessable using concentrations above
220 ptg ml-'. In one hundred and twenty-seven patients fer-
ritin was measured before and after 3 or 4 months of treat-
ment; 49 (39%) were biochemically assessable as above. In
114 patients ferritin was measured before and after 5-7
months of treatment, 48 (42%) were biochemically assess-
able.
Again, during each interval of treatment, a highly
significant association existed between alterations in serum
ferritin (above 220 pg ml-') and clinical assessments of res-
ponse after 6 months (Table II: pre-treatment vs 1-2 months,
x2= 15.1, 1 d.f.; vs 3-4 months, X2 = 23.4, 1 d.f.; vs 5-7
months, x2 = 23, 1 d.f.).
C-reactive protein Only one tumour-free patient presented
with a CRP concentration in excess of 10 mg I`, compared
with 13% (11/87) of those with stage III disease and 53%
(94/179) of those presenting with stage IV disease (Figure 3).
Thus, alterations in CRP have been examined only when
concentrations exceeded 10 mg 1-'.
One hundred and twenty-seven patients with distant meta-
stases had CRP concentrations measured before and after
one or two months of treatment, of whom 70 patients (55%
of the total) were assessable employing CRP concentrations
in excess of 10mg 1-'. One hundred and twenty-six patients
had CRP concentrations measured before and after 3 or 4
months of treatment, 73 (58%) were assessable as above. In
114 patients CRP was measured before and after 5-7
months of treatment, 67 (59%) were biochemically assess-
able.
A highly significant association existed between therapeutic
response (UICC) and alterations in CRP concentration dur-
ing the three time intervals of treatment (Table II: pre-
treatment vs 1-2 months, x2 = 26.52, 1 d.f.; vs 3-4 months,
x2= 30.82, 1 d.f.; vs 5-7 months, x2 = 24.7, 1 d.f).
Orosomucoid Only two control patients presented with an
orosomucoid concentration in excess of 1.2 g -
, compared
with 17% (15/87) of those with stage III disease and 61%
(110 179) of those with stage IV disease (Figure 4). Altera-
tions in concentration during treatment have been examined
only when levels exceeded 1.2 g 1-'.
One hundred and twenty-seven patients with distant meta-
stases had CRP concentrations measured before and after
one or two months of treatment, of whom 70 patients (55%
of the total) were assessable employing CRP concentrations
in excess of 10mg- 1. One hundred and twenty-six patients
had CRP concentrations measured before and after 3 or 4
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Figure 4 Orosomucoid in controls and at presentation of stage
III and IV disease: median concentrations illustrated.
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months of treatment, 73 (58%) were assessable as above. In
114 patients CRP was measured before and after 5-7
months of treatment, 67 (59%) were biochemically assess-
able.
A highly significant association existed between alterations
in marker concentrations during each interval of treatment,
and therapeutic response assessed using UICC criteria after
six months (Table II: pre-treatment vs 1-2 months,
X2= 23.87, 1 d.f.; vs 3-4 months, x2 = 26.4, 1 d.f.; vs 5-7
months, x2 = 22.6, 1d.f).
Erythrocyte sedimentation rate The ESR was greater than
20 mm h-' in only two of 50 tumour-free patients attending
a diagnostic breast clinic (not illustrated). In contrast, the
ESR was greater than 20 mm h-' in 33% (26/79) of patients
presenting with stage III disease and in 66% (115/175) of
those presenting with stage IV disease (Figure 5). Alterations
in the ESR have been examined only above 20mmh-'.
One hundred and twenty-one stage IV patients had ESR
measurements before and after 1 or 2 months of treatment.
Ninety-one (75% of the total) were assessable employing an
ESR of greater than 20mmh-'. One hundred and twelve
patients had the ESR measured before and after 3 or 4
months of treatment, 97 (87%) were assessable. In 111
patients the ESR was measured before and after 5-7 months
of treatment, 91 (82%) were assessable employing an ESR
greater than 20 mm h-'.
Again, a highly significant association existed between
alterations in the ESR during each interval of treatment and
therapeutic response assessed after 6 months using UICC
criteria (Table II: pre-treatment vs 1-2 months, x2 = 12.24,
1 d.f.; vs 3-4 months, x2 = 36.09, 1 d.f.; vs 5-7 months,
x2= 15.21, ld.f).
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Figure 5 ESR at presentation of stage III and IV disease:
median concentrations illustrated.
Combining markers to assess therapeutic response after 3-4
months of treatment
From the results of individuals tumour markers it can be seen
that the accuracy with which each marker was able to assess
response, was highest during the 3-4 month interval of
treatment.
In 127 patients the results of all five markers were available
during this interval of treatment. Patients were considered
biochemically unassessable when the concentrations of all five
markers remained below the minimum levels adopted for
analysis. This occurred in 10 patients (8% of the total). Ofthe
remaining 117 biochemically assessable patients, 37 responded
to treatment (UICC criteria), in 20 disease remained static for 6
months and in 60 disease progressed.
A 'therapeutic index' has been devised by allocating points
according to a rise or a fall in each markerconcentration above
defined levels, as shown in Table III.
Several factors were taken into consideration when construc-
ting the index and different weighting was applied to appropri-
ate alterations in each marker. Progressing disease was
associated with high but stable marker concentrations (score
+ 1). However, high, stable marker concentrations did not
detect disease progression as accurately as increasing marker
concentrations (score + 2). The predictive value for disease
progression of increasing concentrations of ferritin, the ESR
and acute phase proteins (score + 2) was higher than the
predictive value for non-progressing disease offalling concent-
rations (score - 1). Finally, appropriate alterations in CEA
were equally effective to confirm progressing and non-
progressing disease (score + 2 and -2, respectively).
When all five markers increased in concentration by more
than 10%, a maximum index score of + 10 was achieved.
Conversely, when all five markers were abnormal at presenta-
tion and decreased by more than 10%, a minimum index score
of -6 was achieved.
The distribution of index scores at 3-4 months is shown
after subgrouping patients according to UICC assessments of
response at 6 months (Figure 6). By employing a 'cut-off' lying
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Figure 6 Biochemical index scores after 3-4 months.
Table III Allocation of scores towards a biochemical index for response
(values are index scores)
Tumour marker concentrations during treatment
Remain within Decrease Remain Increase
normal limits by 10% stable by 10%
CEA (>6 ngml-') 0 -2 +1 + 2
Ferritin (>220gg I) 0 -I + I + 2
Orosomucoid (>1.2 g ') 0 -I + I + 2
CRP(>lOmgl ') 0 -I + I +2
ESR (>20mmh-') 0 -I +1 +2
+10_
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between index scores of 0 and + 1, the sensitivity that a low
index score has for objective response (or disease stabilisation
for 6 months) is 89.5% (51/57), with a specificity of 78%
(47/60) (Table IV, group A; Figure 7).
When patients with 'marked biochemical change' are con-
sidered separately, (index scores greater than + 2 or less than
-2), the sensitivity for response/stasis increases to 92% (34/37)
with a specificity of 100% (38/38) (Table IV, group B; Figure
8). Seventy-five patients (59% ofthe total) developed 'marked
biochemical' responses to treatment.
Discussion
Significant advances have been made in the treatment of
malignant diseases where specific markers are able to monitor
tumour burden. Two examples are the use of B-HCG assays in
choriocarcinoma (Begent & Bagshaw, 1982) and measurements
of B-HCG and alpha fetoprotein in patients receiving treat-
ment for testicular teratoma (Lange et al., 1976; Schultz et al.,
1978; Lange, 1982). These advances are dependent in part upon
the ability to assess changes in tumour bulk at an early stage,
which allows appropriate alteration of treatment.
This work seeks a marker of tumour burden for advanced
breast cancer so that similar priniciples can be applied. A single
marker with the desired specificity for response has not been
found, even when each marker was examined at high serum
concentrations. However, we have found that a combination of
five markers (at high serum concentration) is able accurately to
reflect therapeutic response of 6 months' duration. The five
assays are easily performed, and their combination is able to
discriminate between response groups at a relatively early stage
of treatment.
Each marker has been considered only at high serum
Table IV Biochemical index scores after 3-4 months' treatment
Group A Group B
UICC assessment A0 >0 <-2 > + 2
Response 35 2 23 0
Static 16 4 1 1 3
Progression 13 47 0 38
(X2 = 51.54;1 d.f.)* (X2 = 70.05; 1 d.f.)*
(P<0.0001) (P<0.0001)
*'Responding' and 'static' patients combined for analysis. Group A:
all assessable patients (n = 117, 91% of total); group B: marked
biochemical changes (n = 75, 59% of total).
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biochemical change' after 3-4 months.
concentrations, to limit interference from factors independent
of tumour burden. Many previous studies have examined
tumour markers in advanced breast cancer with the aim of
assessing response objectively during early treatment. The
majority of these reports can be criticised as the patients
studied were few in number, only single markers were
examined, marker concentrations remained within normal
limits in many patients analysed, and clinical response
criteria were often inadequate.
Several problems are encountered when employing clinical
criteria to assess response retrospectively. They require exten-
sive radiology and repeated measurements oftumour deposits,
making any assessment both difficult and time consuming. As a
result, clinical signs of response may be misinterpreted,
especially when assessments are made on plain X-rays.
Bone is the commonest site for distant metastases from
breast cancer and it is particularly in this situation that
controversy exists over the current criteria for response (Lip-
shitz & Hortobagyi, 1981; Coombes et al., 1983; Hortobagyi et
al., 1984). The development ofsclerosis within lytic metastases
is regarded as a prerequisite for therapeutic response. This is
often slow to develop and may be absent despite unequivocal
evidence ofresponse in other sites. Furthermore, the emergence
of blastic metastases may indicate either response (DeMartini
et al., 1983) or progression ofdisease. As radiological evidence
ofresponse may take many months to appear, it is frequently of
limited value to guide treatment in practice.
In this study, patients with static disease (for a minimum
duration of 6 months) were combined with those showing
objective clinical evidence of response. Previous studies have
indicated that these patients fair as well as responders with
respect to survival (Howell et al., 1984; Williams et al., 1986).
Biochemical responses to treatment, assessed using this com-
bination of markers, were similar in patients showing partial
response or static disease. In contrast, patients with progressive
disease showed markedly different biochemical profiles. It is
submitted that the employment of clinical criteria alone is
inadequate to detect response in many patients found to have
stable disease on clinical grounds.
This biochemical index of response was devised retrospec-
tively. It will require prospective testing on a further series of
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patients to assess its reproducibility. Where biochemical and
clinical assessments of response are at variance, both criteria
should be evaluated against other parameters such as survival.
These studies are currently in progress and if the index is
confirmed as correlating strongly with an assessment of res-
ponse based on UICC criteria, then the biochemical assessment
has several important advantages. These include its simplicity,
objectivity and ability to assess response at an early stage and
thus guide treatment. There are also economic advantages, as
marker estimations amount to only a small proportion of the
costs of limited skeletal surveys.
The UICC criteria were designed to be employed retrospec-
tively and in the context of therapeutic trials only. They are
often not adequate for ongoing assessments of therapeutic
response during treatment. Provided this biochemical measure-
ment of response proves reproducible, it might be possible to
replace clinical criteria for response by this simple and truly
objective alternative.
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